Susquehanna International Group
ITCI

Susquehanna International Group’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Susquehanna International Group’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-262,900
Closed -$34.7M – 14054
2025
Q1 		$34.7M Buy
262,900
+220,400
+519% +$27.5M 0.01% 1263
2024
Q4 		$3.55M Buy
42,500
+6,400
+18% +$526K ﹤0.01% 4150
2024
Q3 		$2.64M Sell
36,100
-106,600
-75% -$8.01M ﹤0.01% 4778
2024
Q2 		$9.77M Sell
142,700
-3,100
-2% -$215K ﹤0.01% 2504
2024
Q1 		$10.1M Buy
145,800
+69,400
+91% +$4.77M ﹤0.01% 2595
2023
Q4 		$5.47M Buy
76,400
+51,000
+201% +$2.93M ﹤0.01% 3554
2023
Q3 		$1.32M Sell
25,400
-32,900
-56% -$1.92M ﹤0.01% 6000
2023
Q2 		$3.69M Sell
58,300
-6,600
-10% -$411K ﹤0.01% 4017
2023
Q1 		$3.51M Sell
64,900
-6,900
-10% -$334K ﹤0.01% 4003
2022
Q4 		$3.8M Sell
71,800
-4,400
-6% -$221K ﹤0.01% 3652
2022
Q3 		$3.55M Buy
76,200
+16,700
+28% +$872K ﹤0.01% 3751
2022
Q2 		$3.4M Sell
59,500
-18,500
-24% -$1.05M ﹤0.01% 3847
2022
Q1 		$4.77M Buy
78,000
+1,000
+1% +$51.9K ﹤0.01% 3711
2021
Q4 		$4.03M Sell
77,000
-23,000
-23% -$966K ﹤0.01% 4112
2021
Q3 		$3.73M Sell
100,000
-28,500
-22% -$991K ﹤0.01% 4499
2021
Q2 		$5.25M Sell
128,500
-172,400
-57% -$6.37M ﹤0.01% 3957
2021
Q1 		$10.2M Buy
300,900
+21,400
+8% +$742K ﹤0.01% 2738
2020
Q4 		$8.89M Sell
279,500
-165,100
-37% -$4.34M ﹤0.01% 2633
2020
Q3 		$11.4M Buy
444,600
+132,700
+43% +$3.03M ﹤0.01% 2026
2020
Q2 		$8.01M Buy
311,900
+107,300
+52% +$2.17M ﹤0.01% 2401
2020
Q1 		$3.15M Sell
204,600
-1,025,800
-83% -$22.3M ﹤0.01% 3212
2019
Q4 		$42.2M Buy
1,230,400
+483,000
+65% +$5.8M 0.01% 920
2019
Q3 		$5.58M Buy
747,400
+423,500
+131% +$4.06M ﹤0.01% 2578
2019
Q2 		$4.2M Buy
323,900
+235,800
+268% +$3.02M ﹤0.01% 2950
2019
Q1 		$1.07M Sell
88,100
-6,000
-6% -$76.7K ﹤0.01% 4902
2018
Q4 		$1.07M Buy
94,100
+20,400
+28% +$329K ﹤0.01% 4542
2018
Q3 		$1.6M Sell
73,700
-193,900
-72% -$4.05M ﹤0.01% 4360
2018
Q2 		$4.73M Sell
267,600
-14,500
-5% -$294K ﹤0.01% 2777
2018
Q1 		$5.94M Buy
282,100
+198,100
+236% +$3.86M ﹤0.01% 2333
2017
Q4 		$1.22M Sell
84,000
-95,000
-53% -$1.47M ﹤0.01% 4855
2017
Q3 		$2.83M Buy
179,000
+132,800
+287% +$1.95M ﹤0.01% 3319
2017
Q2 		$574K Sell
46,200
-61,000
-57% -$707K ﹤0.01% 6390
2017
Q1 		$1.74M Buy
107,200
+35,100
+49% +$508K ﹤0.01% 3982
2016
Q4 		$1.09M Buy
72,100
+22,100
+44% +$312K ﹤0.01% 5345
2016
Q3 		$762K Sell
50,000
-67,900
-58% -$2.75M ﹤0.01% 5311
2016
Q2 		$4.58M Buy
117,900
+39,800
+51% +$1.43M ﹤0.01% 2325
2016
Q1 		$2.17M Buy
78,100
+1,700
+2% +$56.7K ﹤0.01% 3614
2015
Q4 		$4.11M Sell
76,400
-60,400
-44% -$3.05M ﹤0.01% 2795
2015
Q3 		$5.48M Buy
136,800
+96,300
+238% +$3.14M ﹤0.01% 2544
2015
Q2 		$1.29M Buy
+40,500
New +$1.03M ﹤0.01% 5648

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Susquehanna International Group's ITCI Position: Q1 2025 in Review

Susquehanna International Group sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2025, closing a stake of 9,286 shares — an estimated $1.16M sold.

Susquehanna International Group first reported a position in ITCI in Q2 2014 and held it in 34 quarters. The position peaked at $17.4M in Q3 2017. 395 funds tracked by Wall St. Rank hold ITCI as of Q1 2025.

  • Susquehanna International Group reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2025 after selling out during the quarter.
  • Susquehanna International Group sold 9,286 Intra-Cellular Therapies Inc. shares in Q1 2025, an estimated $1.16M.
  • Susquehanna International Group first reported a position in Intra-Cellular Therapies Inc. in Q2 2014 and held it in 34 quarters.
  • Susquehanna International Group's Intra-Cellular Therapies Inc. position peaked at $17.4M in Q3 2017.
  • 395 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2025.

Based on Susquehanna International Group's 13F filing for Q1 2025, filed 14 May 2025.